Imagine a five-year-old boy whose life hangs in the balance due to a devastating rare disease, and the one medication that could turn things around is being denied by the national health system. This is the gut-wrenching plight of little Idrees, and it's a story that raises tough questions about fairness in healthcare. But here's where it gets controversial: should taxpayers foot the bill for pricey treatments for a handful of patients, or should resources go toward broader public health needs? Let's dive into this emotional tale and uncover the facts that most people miss about rare diseases and drug funding decisions.
At just five years old, Idrees Qasim's belly was so distended that walking became a real struggle for him. Unless he was in his stroller, he relied on his parents to carry him everywhere. Being smaller than average for his age, timid, and overly careful with physical activities, Idrees faced bullying at school and couldn't match the energy of his seven-year-old sister, Eliza, during playtime at their home in Oxford.
As a true 'daddy's boy,' Idrees was slow to start walking and talking, and while he didn't show signs of pain, his unusually rounded tummy worried his father, Qasim, a 43-year-old hotel receptionist. Concerned, Qasim brought Idrees to the family doctor at age two, and again at three when the swelling persisted. It wasn't until Idrees turned four that the doctor flagged it as a serious issue and arranged for a scan, revealing that his liver was three or four times larger than it should be.
Further blood tests and additional scans confirmed that his lungs were also impacted. In March of last year, doctors at Great Ormond Street Hospital (GOSH) in London diagnosed Idrees with Niemann-Pick type B (NPB), a highly uncommon metabolic condition. NPB affects roughly 40 individuals in the UK and Ireland, leading to the accumulation of a harmful fatty substance in the lungs, liver, and spleen. This happens because the body lacks a crucial enzyme called sphingomyelinase, which normally breaks down this substance. As a result, breathing becomes challenging, and the liver and spleen swell up, putting immense strain on the body. For context, Niemann-Pick is part of a group of about 50 inherited lysosomal storage disorders, where a defective enzyme causes waste to pile up inside cells—think of it like a clogged garbage disposal in your body's recycling system.
Qasim, reflecting on his research after the diagnosis, shared that the John Radcliffe Hospital in Oxford had never seen another case. 'I can still picture searching online and seeing the grim phrases "no effective treatment" and "life expectancy into late childhood or early teens." It shattered us completely,' he recalled.
For most patients with these disorders until recently, the only path was to manage symptoms palliatively as they worsened painfully due to organ enlargement. In the more severe type A version of Niemann-Pick, the fatty buildup also affects the brain, often leading to death in infancy from breathing failure and neurological decline. Those with type B typically don't live past their teenage years.
But just over a year after his diagnosis, Idrees is now mimicking his sister's somersaults across the living room, all thanks to a groundbreaking treatment called olipudase alfa, marketed by Sanofi as Xenpozyme. This lab-created enzyme replacement therapy shrinks the spleen and liver while boosting lung function. Administered via infusions every two weeks, it's proven to extend lifespans for NPB patients by about 30 years. And this is the part most people miss: treatment must continue for life, offering hope where there was none.
'When the GOSH specialists introduced us to Xenpozyme, they called it a total game-changer,' Qasim explained. 'It felt like a rescue rope tossed to us in our darkest hour.'
Yet, there's a harsh twist. Kids in over 50 countries, including two in Scotland, receive Xenpozyme, but in April 2024, the National Institute for Health and Care Excellence (NICE) rejected it for NHS coverage due to cost concerns. This leaves Idrees and about 35 other Niemann-Pick patients in England, Wales, and Northern Ireland without access. Consequently, Idrees journeys to GOSH biweekly with Qasim for a three-hour infusion, receiving the drug through Sanofi's compassionate program. Sanofi assured Good Health that 'existing supplies for current patients won't be disrupted by the NICE ruling,' but for Idrees's parents—Qasim and Sadia, a 36-year-old retail worker—the situation feels precarious.
'Every time I see Idrees joyfully playing with his toy cars, my heart aches from the uncertainty,' Qasim admitted. 'As long as the medication keeps coming, he's leading a normal life—but we're walking on thin ice. If it stops, we'll have to watch him deteriorate.'
The family, including Qasim's mother Nasreen, a 60-year-old accountant, has pondered relocating to Scotland for treatment. 'We'd relocate anywhere globally to secure what our son desperately needs,' Nasreen stated. 'But right now, it's unclear if Scotland will keep funding it after their upcoming review next year. We're trapped, trying to cherish each day while the future remains a mystery.'
In the UK, around 3.5 million people—about one in 17—live with rare diseases, a number comparable to cancer cases. Shockingly, 95% of these individuals lack any available treatment. This stems from the hefty development costs and limited patient pools, which discourage pharmaceutical companies from pursuing these 'orphan' drugs. To address this, 2013 legislation provided incentives like subsidies and tax breaks for orphan drugs. Still, medications such as Xenpozyme—developed over 30 years—rarely get NICE approval due to affordability issues.
NICE evaluates drugs by assessing if their benefits justify the price, using quality-adjusted life years (QALYs)—a measure combining extra life years with improved well-being. For instance, if a drug costs under £20,000 per QALY, it's usually deemed worthwhile. For ultra-rare conditions like NPB (affecting fewer than one in 50,000 people), the bar rises to £50,000 to £300,000 per QALY. Negotiations between NICE and Sanofi stalled because they couldn't agree on a price under that £300,000 cap.
A NICE spokesperson told Good Health: 'The company and NHS England engaged in multiple discussions but couldn't settle on a cost-effective price for olipudase alfa.' Sanofi countered: 'We proposed various solutions to ensure access, but unfortunately, no agreement fit within the rigid framework.'
Scotland's Medicines Consortium approved Xenpozyme in 2023 via an ultra-orphan pathway, granting three years of early use to collect more data. But here's where it gets controversial: Idrees's case isn't isolated—it's a microcosm of larger debates. In August, negotiations between Health Secretary Wes Streeting and pharma firms collapsed after prolonged talks. Streeting vowed not to let companies 'exploit' taxpayers with exorbitant prices, while giants like Novartis and AstraZeneca warned that the UK's 'diminishing market appeal' could deny patients cutting-edge treatments found elsewhere.
A Department of Health and Social Care spokesperson said: 'We're aware of the distress from NICE's Xenpozyme decision and it's regrettable Sanofi didn't offer a more reasonable deal. NICE has endorsed numerous rare disease treatments where pricing aligned with benefits.'
Yet, data from the Association of the British Pharmaceutical Industry reveals over 60 European-available drugs are inaccessible in the UK in the last five years. Gilead Sciences, for example, pulled Trodelvy from NICE review for certain breast cancer due to unprofitable UK pricing demands.
Amid these tensions, patients like Idrees bear the brunt. With no alternative for Niemann-Pick—only symptom management—consultant Alex Broomfield at GOSH notes: 'Symptoms worsen with age, so care focuses on easing them.' Toni Mathieson, CEO of Niemann-Pick UK and mother to three children who passed from type A in infancy, calls NICE's ruling 'heartbreaking.' After losing Hannah and Samuel in 2004 and Lucy in 2007, she's advocated tirelessly for Xenpozyme. 'Their evaluations overlook the high R&D costs for tiny groups and the full burdens of rare diseases on families,' she argues. 'This delays access compared to places like Germany, France, and the US.'
Xenpozyme costs £3,612 per 20mg vial (plus VAT), with doses based on weight—for Idrees at 17kg, annual treatment hits about £282,000. Toni estimates £20 million yearly for all 40 UK children, a tiny NHS budget slice. But is this fair? Should the NHS invest more in extending lives for the few, or bolster services for everyone? Consider the long-term caregiving costs for ill children too.
'It could revolutionize lives for these patients,' Toni adds. 'How do you value a human life?' Nasreen recalls Idrees sobbing on diagnosis day: 'Hope seemed extinct.' Two months post-treatment, his physique transformed. 'I hesitate to say 'miraculous,' but that's how it was—his organs nearly normalized, tummy vanished, and he started running, playing, and thriving at school.'
For now, Idrees continues with Xenpozyme, but another child won't get that chance. 'We're deeply thankful, but this transcends Idrees,' Nasreen says. 'The idea of others enduring needless suffering and death is intolerable.'
What do you think? Should rare disease treatments get priority funding, even if it means higher costs for everyone? Or should the NHS stick to broader allocations? Do you agree NICE's thresholds are too strict, or do they protect taxpayers? Share your views in the comments—we'd love to hear diverse perspectives! For more info, visit npuk.org.
